CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 329 enrolled
Drug / intervention
Bodyport Cardiac Scaledevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04882449
NCT04882449N/ACompleted

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events - SCALE-HF1

Bodyport Inc.·observational·Posted May 12, 2021·Updated Feb 10, 2025

In Brief

An observational study evaluating Bodyport Cardiac Scale for Heart Failure. Completed, enrolled 329 participants across 8 sites.

Detailed Summary

The main goal of this study is to use data from the Bodyport Cardiac Scale to help detect of worsening heart failure (HF) early.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMay 12, 2021
Enrollment StartJul 8, 2021
Primary CompletionApr 30, 2023
Study CompletionJul 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.1 years ago

Interventions

Bodyport Cardiac Scaledevice

The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.